

# Pau Montesinos

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3963960/pau-montesinos-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151  
papers

4,816  
citations

31  
h-index

66  
g-index

170  
ext. papers

6,205  
ext. citations

4.8  
avg. IF

5.17  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 151 | Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1728-1740   | 59.2 | 413       |
| 150 | Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , <b>2019</b> , 33, 379-389   | 10.7 | 287       |
| 149 | Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , <b>2008</b> , 111, 3395-402  | 2.2  | 258       |
| 148 | Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , <b>2010</b> , 115, 5137-46   | 2.2  | 234       |
| 147 | Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i> , <b>2009</b> , 113, 775-83  | 2.2  | 232       |
| 146 | Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , <b>2019</b> , 133, 1630-1643   | 2.2  | 219       |
| 145 | Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i> , <b>2020</b> , 135, 2137-2145  | 2.2  | 216       |
| 144 | Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 984-997  | 21.7 | 182       |
| 143 | Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1505-10 | 2.2  | 181       |
| 142 | Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. <i>Haematologica</i> , <b>2008</b> , 93, 67-74  | 6.6  | 148       |
| 141 | Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , <b>2008</b> , 112, 3130-4  | 2.2  | 129       |
| 140 | International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1919-26   | 2.2  | 126       |
| 139 | Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2526-2537   | 59.2 | 100       |
| 138 | Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , <b>2011</b> , 117, 1799-805  | 2.2  | 95        |
| 137 | How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 2777-82  | 2.2  | 86        |
| 136 | Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. <i>Haematologica</i> , <b>2009</b> , 94, 1242-9  | 6.6  | 78        |
| 135 | Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 86-94  | 4.7  | 74        |

|     |  |      |    |
|-----|--|------|----|
| 134 | Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , <b>2018</b> , 2, 923-932   | 7.8  | 73 |
| 133 | Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , <b>2010</b> , 95, 424-31   | 6.6  | 72 |
| 132 | The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2011</b> , 3, e2011059   | 3.2  | 59 |
| 131 | Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1115-1153  | 3    | 55 |
| 130 | EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 397-402   | 4.4  | 54 |
| 129 | Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. <i>Leukemia</i> , <b>2015</b> , 29, 1084-91   | 10.7 | 53 |
| 128 | Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , <b>2011</b> , 96, 1470-7  | 6.6  | 48 |
| 127 | Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 730-40                            | 4.7  | 45 |
| 126 | Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , <b>2020</b> , 7, e601-e612  | 14.6 | 41 |
| 125 | Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , <b>2018</b> , 132, 2736-2736 | 2.2  | 36 |
| 124 | A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 700-10   | 4.5  | 36 |
| 123 | Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 78-81  | 4.5  | 35 |
| 122 | Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , <b>2021</b> , 35, 62-74   | 10.7 | 34 |
| 121 | A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2018</b> , 97, 763-772  | 3    | 32 |
| 120 | Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. <i>Annals of Hematology</i> , <b>2014</b> , 93, 299-307   | 3    | 31 |
| 119 | Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1725-30   | 4.7  | 30 |
| 118 | Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , <b>2016</b> , 12, 293-302   | 3.6  | 30 |
| 117 | Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study. <i>Blood</i> , <b>2016</b> , 128, 4060-4060                         | 2.2  | 29 |

|     |   |      |    |
|-----|---|------|----|
| 116 | Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1589-95  | 4.7  | 28 |
| 115 | Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 1307-1312   | 4.4  | 28 |
| 114 | Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1465-72  | 4.4  | 26 |
| 113 | MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine + idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , <b>2020</b> , 16, 807-815  | 3.6  | 26 |
| 112 | Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 1084-8   | 4.4  | 26 |
| 111 | Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , <b>2016</b> , 40, 1-9  | 2.7  | 25 |
| 110 | A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 288-296  | 6.6  | 24 |
| 109 | Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 305-18  | 2    | 24 |
| 108 | Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1197-1206  | 1.9  | 23 |
| 107 | Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Study. <i>Blood</i> , <b>2019</b> , 133, 562-563 | 2.2  | 23 |
| 106 | Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1463-1470   | 4.7  | 22 |
| 105 | Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1387-92  | 4.7  | 20 |
| 104 | Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 358-366  | 4.7  | 20 |
| 103 | Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 109-18  | 3.5  | 19 |
| 102 | Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , <b>2020</b> , 34, 3149-3160   | 10.7 | 19 |
| 101 | A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , <b>2012</b> , 118, 410-7  | 6.4  | 19 |
| 100 | First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4260-4273  | 2.2  | 19 |
| 99  | Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. <i>Leukemia</i> , <b>2018</b> , 32, 21-29   | 10.7 | 18 |

|    |  |      |    |
|----|--|------|----|
| 98 | Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , <b>2019</b> , 134, 231-231 | 2.2  | 18 |
| 97 | -mutated relapsed or refractory AML: current challenges and future prospects. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , <b>2019</b> , 9, 19-32  | 2.6  | 17 |
| 96 | Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 92   | 22.4 | 17 |
| 95 | Pharmacogenomics and the treatment of acute myeloid leukemia. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1245-1278  | 2.8  | 17 |
| 94 | Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. <i>Current Drug Metabolism</i> , <b>2018</b> , 19, 55-74  | 3.5  | 16 |
| 93 | Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial <b>2019</b> ,   |      | 16 |
| 92 | Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , <b>2020</b> , 105, e294-e297   | 6.6  | 15 |
| 91 | A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation. <i>International Journal of Hematology</i> , <b>2007</b> , 86, 186-92   | 2.3  | 15 |
| 90 | Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 228-240   | 5.1  | 15 |
| 89 | Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. <i>Blood</i> , <b>2021</b> , 137, 1879-1894   | 2.2  | 15 |
| 88 | T cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1060-3                         | 4.7  | 14 |
| 87 | Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2081-2088  | 3    | 13 |
| 86 | Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. <i>Leukemia</i> , <b>2020</b> , 34, 2333-2341   | 10.7 | 13 |
| 85 | Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2014</b> , 93, 43-6  | 3    | 13 |
| 84 | Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 79-86  | 3.8  | 13 |
| 83 | Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1113-1120                               | 1.9  | 12 |
| 82 | Emerging strategies for the treatment of older patients with acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1583-93   | 3    | 12 |
| 81 | Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. <i>Blood Reviews</i> , <b>2020</b> , 44, 100675   | 11.1 | 11 |

|    |   |      |    |
|----|---|------|----|
| 80 | Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. <i>Blood</i> , <b>2019</b> , 134, 14-14  | 2.2  | 11 |
| 79 | Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1989-2007  | 3    | 11 |
| 78 | Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. <i>BMC Cancer</i> , <b>2018</b> , 18, 1100  | 4.8  | 11 |
| 77 | Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 146-154  | 1.9  | 10 |
| 76 | Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1634-1643  | 1.9  | 9  |
| 75 | A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , <b>2019</b> , 76, 1-10   | 2.7  | 9  |
| 74 | Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 138, 6-13   | 7    | 8  |
| 73 | Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1220-1225  | 1.9  | 8  |
| 72 | Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the PetHEMA ALL-HR-11 Trial. <i>Blood</i> , <b>2015</b> , 126, 1333-1333 | 2.2  | 8  |
| 71 | Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1181-1194   | 3    | 8  |
| 70 | Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 2358-2370   | 10.7 | 8  |
| 69 | Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1077-1084   | 3    | 7  |
| 68 | Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. <i>Cancer</i> , <b>2019</b> , 125, 2810-2817  | 6.4  | 7  |
| 67 | Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 1199-1209  | 3.6  | 7  |
| 66 | Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2018</b> , 132, 30-30  | 2.2  | 7  |
| 65 | Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , <b>2021</b> ,   | 10.7 | 7  |
| 64 | Evolving treatment patterns and outcomes in older patients (≥80 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , <b>2021</b> , 35, 1571-1585  | 10.7 | 7  |
| 63 | Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 197-218   | 3.8  | 6  |

|    |   |      |   |
|----|---|------|---|
| 62 | A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , <b>2020</b> , 9, 2317-2329  | 4.8  | 6 |
| 61 | Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 388-395   | 4.7  | 6 |
| 60 | Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 512-6   | 4.7  | 6 |
| 59 | QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML). <i>Annals of Oncology</i> , <b>2017</b> , 28, v370 | 10.3 | 5 |
| 58 | Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , <b>2016</b> , 16, 1-2   | 3.5  | 5 |
| 57 | Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2019</b> , 58, 815-819   | 5    | 5 |
| 56 | Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2467-2483   | 3    | 5 |
| 55 | Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , <b>2021</b> , 106, 3079-3089  | 6.6  | 5 |
| 54 | Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2928-2938  | 1.9  | 5 |
| 53 | A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. <i>Cancer</i> , <b>2021</b> , 127, 2003-2014  | 6.4  | 5 |
| 52 | Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , <b>2018</b> , 10,  | 6.6  | 5 |
| 51 | Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, S231   | 2    | 4 |
| 50 | The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , <b>2019</b> , 186, 263-268   | 4.5  | 4 |
| 49 | Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1754-1758                           | 4.7  | 4 |
| 48 | Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1146-1155  | 1.9  | 4 |
| 47 | Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, S228-S229   | 2    | 3 |
| 46 | Differences in Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2019</b> , 11, e2019016   | 3.2  | 3 |
| 45 | Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment. <i>Revista Iberoamericana De Micologia</i> , <b>2015</b> , 32, 185-9  | 1.6  | 3 |

|    |   |     |   |
|----|---|-----|---|
| 44 | Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 672-683  | 4.5 | 3 |
| 43 | Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.. <i>Blood</i> , <b>2022</b> ,   | 2.2 | 3 |
| 42 | Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , <b>2021</b> ,   | 7.8 | 3 |
| 41 | Real life outcomes of patients aged ≥5 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2720-2732  | 1.9 | 2 |
| 40 | Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e513-e522 | 2   | 2 |
| 39 | Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. <i>Scientific Reports</i> , <b>2020</b> , 10, 5904   | 4.9 | 2 |
| 38 | Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older. <i>Blood</i> , <b>2013</b> , 122, 2687-2687   | 2.2 | 2 |
| 37 | Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 162-169   | 3.8 | 2 |
| 36 | Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 3287-3305   | 1.9 | 2 |
| 35 | Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 614215  | 5.3 | 2 |
| 34 | A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1497-1508   | 3   | 2 |
| 33 | Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain. <i>Journal of Clinical Apheresis</i> , <b>2021</b> , 36, 612-620                        | 3.2 | 2 |
| 32 | PF261 A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF SELINEXOR VERSUS PHYSICIAN'S CHOICE (PC) IN OLDER PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML). <i>HemaSphere</i> , <b>2019</b> , 3, 82-83   | 0.3 | 2 |
| 31 | Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <i>Mycoses</i> , <b>2019</b> , 62, 418-427   | 5.2 | 2 |
| 30 | Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 735-746  | 7.1 | 2 |
| 29 | 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 163   | 7   | 2 |
| 28 | Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry. <i>Blood</i> , <b>2020</b> , 136, 25-27   | 2.2 | 1 |
| 27 | Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.. <i>Expert Opinion on Emerging Drugs</i> , <b>2022</b> , 1-18   | 3.7 | 1 |

|    |  |     |   |
|----|--|-----|---|
| 26 | Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial). <i>Blood</i> , <b>2020</b> , 136, 22-22  | 2.2 | 1 |
| 25 | Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 167   | 7   | 1 |
| 24 | PF277 ALICE: AN AML STUDY WITH LSD1 INHIBITION IN COMBINATION WITH AZACITIDINE IN THE ELDERLY. <i>HemaSphere</i> , <b>2019</b> , 3, 90   | 0.3 | 1 |
| 23 | Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 227-235   | 3.2 | 1 |
| 22 | Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 1057-1065  | 2.8 | 1 |
| 21 | Updated results from DIAMOND-01 (CL124-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7023-7023                           | 2.2 | 1 |
| 20 | The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , <b>2021</b> , 13,  | 6.6 | 1 |
| 19 | Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs. <i>Medicina Clínica</i> , <b>2021</b> , 156, 573-574   | 1   | 1 |
| 18 | Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain. <i>PharmacoEconomics - Open</i> , <b>2019</b> , 3, 229-235                  | 2.1 | 1 |
| 17 | Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 83-87                                      | 4.7 | 1 |
| 16 | Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 659-668                        | 1.9 | 1 |
| 15 | A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 3192-3203  | 1.9 | 1 |
| 14 | Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , <b>2021</b> , 127, 4421-4431  | 6.4 | 1 |
| 13 | Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 71  | 7   | 1 |
| 12 | Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. <i>Blood</i> , <b>2020</b> , 136, 33-35 | 2.2 | 0 |
| 11 | A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 175   | 7   | 0 |
| 10 | Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 724-733                                     | 3.8 | 0 |
| 9  | Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. <i>Hematological Oncology</i> , <b>2021</b> , 39, 529-538                                     | 1.3 | 0 |

|   |   |     |   |
|---|---|-----|---|
| 8 | Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.. <i>Leukemia Research</i> , <b>2022</b> , 115, 106821   | 2.7 | 0 |
| 7 | Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 246-249 | 1.9 |   |
| 6 | Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience. <i>Blood</i> , <b>2020</b> , 136, 2-3  | 2.2 |   |
| 5 | Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2727-2736  | 1.9 |   |
| 4 | Current status of acute myeloid leukaemia in Spain: Results from a Delphi study on its epidemiology, disease management and unmet clinical needs. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 156, 573-574  | 0.3 |   |
| 3 | Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study. <i>Leukemia Research</i> , <b>2020</b> , 92, 106352   | 2.7 |   |
| 2 | Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a mutation. <i>Future Oncology</i> , <b>2021</b> , 17, 215-227  | 3.6 |   |
| 1 | Secondary AML. <i>Hematologic Malignancies</i> , <b>2021</b> , 71-101   | 0   |   |